



4TH INTERNATIONAL CONFERENCE ON
DRUG DISCOVERY
DEVELOPMENT AND LEAD OPTIMIZATION

DECEMBER 3-5, 2018

Venue

DoubleTree by Hilton
San Francisco International Airport
835 Airport Blvd
Burlingame, CA 94010
USA

PROGRAM



Venue Floor Plan

Will upadte soon..

DAY-1 PROGRAM
MONDAY, DECEMBER 3, 2018

08:15 Registrations

09:15 *Introduction and Welcome address by Conference Chairman – Prof. Harlod Smith, Rochester University, NY, USA*

Plenary Session (Talk: 30 Min | Q&A: 10 Min)

09:30 **Ferid Murad**, *George Washington University, Washington DC, USA*
Discovery of Nitric Oxide and Cyclic GMP in Cell Signaling and Their Role in Drug Discovery and Development

10:10 **Coffee Break**

Keynote Session (Talk: 25 Min | Q&A: 5 Min)

10:30 **Philip S. Low**, *Purdue University, IN, USA*
Sensitive Control of CAR T Cell Properties with Low Molecular Weight Drugs

11:00 **Troels Koch**, *Roche Innovation Center Copenhagen, Denmark*
New Drug Discovery Concepts for Locked Nucleic Acid (LNA) Therapeutics

11:30 **Wendy Cornell**, *IBM – Healthcare and Life Sciences Research, USA*
AI in Drug Target Identification and Drug Discovery

12:00 **Dawei Li**, *Shanghai Jiao Tong University, China*
Antibody Targeting of the Tumor Tissue Signalling in Solid Tumors

12:30 **Lunch & Networking**

Symposium-I (Talk: 20 Min | Q&A: 5 Min)

Symposium: Accelerating Drug Discovery and Development Through Academic Collaborations

Chair: Thomas D.Y. Chung, Sanford Burnham Prebys Medical Discovery Institute, CA, USA

13:30 **Thomas D.Y. Chung**, *Director, Translational Programs Outreach, SBP Medical Discovery Institute, CA, USA*
Accelerating Translational Research into Drug Discovery in Academia through Strategic Partnerships

13:55 **Stephanie C. Oestreich**, *Head BRIDGEs Partnerships North America, Evotec*
Bridging the Drug Discovery Gap

14:20 **Jadwiga Bienkowska**, *Oncology Translational Research, Pfizer, CA, USA*
Watson Analytics: AI Research Assistant for Drug Discovery in Oncology

DAY-1 PROGRAM

MONDAY, DECEMBER 3, 2018

14:45 **Dean G. Brown**, Director of External Chemistry, Hit Discovery, Discovery Sciences
IMED Biotech Unit, AstraZeneca, MA, USA

The Use of an Open Innovation Discovery Model at AstraZeneca to Access Novel Targets

15:10 Coffee Break

15:30 **Michelle Arkin**, Co-director, Small Molecule Discovery Center (SMDC), San Francisco, CA, USA

A Consortium-Based Approach to Academic Drug Discovery

15:55 **Christine Brideau**, Vice President, In Vitro Biology, Research Service Division (RSD), WuXi AppTec, NJ, USA

Perspectives on Building Effective Partnerships Between CROs and Academia

16:20 **Anuradha Roy**, Director, High Throughput Screening Laboratory, University of Kansas, KS, USA

Early Drug Discovery in Academia

Sponsor Talk (Talk: 12 Min | Q&A: 3 Min)

16:45 **Whitney Smith**, Director, Business Development, Collaborative Drug Discovery Inc., CA, USA

Lessons Learned While Deploying Present and Developing Future Collaborative Informatics Innovations

17:00 Wine Reception & Poster Session

DAY-1 PROGRAM

MONDAY, DECEMBER 3, 2018

17:00 – 19:00 Poster Presentations

- DD-1** **Yung-Chiao Chang**, National Health Research Institutes, Miaoli, Taiwan, R.O.C.
Pharmacological Studies of Mice with Humanized Mu-Opioid Receptor
- DD-2** **Megan L. Kelly**, Duke University School of Medicine, Durham NC, USA
RNA Structural Complexity as Determinant of Small Molecule Binding Specificity
- DD-3** **Saurabh Srivastava**, King George's Medical University, Lucknow, UP, India
Chemoprotective Effect of Nano-Curcumin on 5-Fluorouracil Induced Chemo-toxicity Toward Oral Cancer Treatment
- DD-4** **Jinal Patel**, The University of Auckland, Auckland, New Zealand
Intrinsic Fluorescence Spectroscopy and Molecular Modelling Lead to the Development of New Tyrosyl-DNA Phosphodiesterase 1 Inhibitors
- DD-5** **Cemal Kopruluoglu**, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Czech Republic
Quantum Mechanical Investigation of Non-Covalent Interactions in Protein-Ligand Complexes
- DD-6** **Sarah El-Lakany**, Alexandria University, Alexandria, Egypt
Electrospun Crosslinked-Zein Scaffolds for Accelerating Wound Healing in Rats
- DD-7** **Daniel Feder**, University of Queensland, Australia
TBA
- DD-8** **Heather Arnaz**, Collaborative Drug Discovery, Burlingame, CA, USA
Innovative Approaches for Secure, Modern Collaborative Drug Discovery
- DD-9** **I. Hayes**, Biosensor and Assay Solutions, Agilent Technologies, Ireland
Multiplexed Cell-Based Screening of Drug-Induced Metabolic Dysfunction and Cytotoxicity
- DD-10** **Saltuk Mustafa Eyrilmez**, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Czech Republic
TBA
- DD-11** **Chia-Chieh Chu**, Duke University, USA
TBA

DAY-1 PROGRAM

MONDAY, DECEMBER 3, 2018

- DD-12** *Chrysanthi Alexandri*, *Université Libre de Bruxelles – Belgium*
Identification and Efficiency Assessment of Potential miRNAs Targets for Developing New Pharmacological Drugs Against Chemotherapy- Induced Ovarian Damage Using Mice Model
- DD-13** *Ming-Hsien Chan*, *National Taiwan University, Taipei, Taiwan*
A Theranostic Nanobubble Encapsulating a Drug assistant Upconversion Hybrid Nanosystem for Targeted Cancer Therapy
- DD-14** *Munefumi Torihata*, *Daiichi Sankyo Company Ltd., Japan*
TBA

Poster Slots Available

DAY-2 PROGRAM
TUESDAY, DECEMBER 4, 2018**Symposium-II (Talk: 20 Min | Q&A: 5 Min)****Symposium: Target Validation and Lead Optimization**

Chairs: *Christine Brideau*, Vice President, In Vitro Biology, WuXi AppTec, NJ, USA
Ryan Bennett, OyaGen, Inc., Rochester NY, USA

- 08:00** *Ryan Bennett*, Chief Scientific Officer, OyaGen, Inc., Rochester NY, USA
Drug Development Utilizing Targets within an Interactome
- 08:25** *Howard Maibach*, Professor, UCSF School of Medicine, San Francisco, CA, USA
Innovation from Academic Dermatology
- 08:50** *Weian Zhao*, Sue and Bill Gross Stem Cell Research Center University of California, Irvine, CA, USA
Targeting Biophysical Cues to Study, Diagnose, and Treat Cancer
- 09:15** *Thomas Webster*, Northeastern University, MA, USA
Antibiotic Resistant Bacteria, Chemotherapeutic Resistant Cancer Cells:
Conventional Drug Therapy Needs a Nano Face Lift
- 09:40** **Coffee Break**
- 10:00** *Adam R. Renslo*, Director of Chemistry, University of California, San Francisco, CA, USA
Ferrous Iron Dependent Pharmacology in Cancer and Infectious Disease
- 10:25** *Jikui Song*, University of California, Riverside, CA, USA
Perspectives for Zika Virus NS5 Protein as a Drug Target
- 10:50** *Harris Andrew Gelbard*, University of Rochester School of Medicine and Dentistry, NY, USA
Broad-spectrum Mixed Lineage Kinase Inhibition for Treatment of Multiple End Organ Diseases with Inflammation

DAY-2 PROGRAM

TUESDAY, DECEMBER 4, 2018

Short Talk (Talk: 12 Min | Q&A: 3 Min)

- 11:15** **Eric Martin**, Director, Computational Chemistry, Novartis Institutes for BioMedical Research, Inc., CA, USA
Massively Multi-Target Profile-QSAR 2.0: Predictions as Accurate as 4-point IC50s for Most Novartis Assays
- 11:30** **Kamil Paruch**, Department of Chemistry, Masaryk University, Czech Republic
Furo[3,2-b]pyridine – A Novel Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway
- 11:45** **Ravindra Peravali**, Head, Screening Center, ITG, Karlsruhe Institute of Technology, Germany
Zebrafish as a Model Organism for Drug Discovery and Testing
- 12:00** **Reem Al Olaby**, College of Health Sciences, California Northstate University, California, USA
Ligands 7962 & 73735: Drug Leads That Inhibit Infection with *Plasmodium falciparum*, *Plasmodium bergeri* and *Plasmodium yoelii*
- 12:15** TBA
TBA
- 12:30** **Lunch & Networking**

Symposium-III (Talk: 20 Min | Q&A: 5 Min)

Symposium: RNA as a Drug, Drug Target and Gene Editing Tool in Target Validation

Chairs: **Troels Koch**, VP & Head of Research, RNA Therapeutics, Roche Innovation Center Copenhagen, Denmark
Ailong Ke, Department of Molecular Biology and Genetics, Cornell University, NY, USA

- 13:30** **Elliott Nickbarg**, Merck Research Laboratories, Boston, MA, USA
Investigating Non-coding RNAs as Small Molecule Drug Targets using Affinity-Selection Mass Spectrometry
- 13:55** **Dirk Daelemans**, KU Leuven, Rega Institute, Belgium
Target Deconvolution of Small-Molecules by CRISPR/Cas-Mediated Resistance Mutagenesis Scanning

DAY-2 PROGRAM

TUESDAY, DECEMBER 4, 2018

-
- 14:20** **Susana Valente**, Department of Immunology and Microbiology, The Scripps Research Institute, FL, USA
Silencing of the HIV Reservoir with a Potent Tat Inhibitor
- 14:45** **Ailong Ke**, Department of Molecular Biology and Genetics, Cornell University, NY, USA
Structure, Mechanism, and Potential Applications of the Type I CRISPR-Cas System
- 15:10** **Coffee Break**
-
- 15:30** **Rocco G. Gogliotti**, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, TN, USA
Cross-species Expression Profiling for Improved Target Selection in Rett Syndrome
- 15:55** **Hashim M Al-Hashi**, Director, Duke Center for RNA Biology, Duke University, NC, USA
Dynamic Ensemble-based Discovery of Small Molecules Targeting RNA

Short Talk (Talk: 12 Min | Q&A: 3 Min)

- 16:20** **Stine Jørgensen**, Senior Scientist, Vipergen ApS, Denmark
Nanomolar Inhibitor for Hexamer DNA Helicase RuvBL1/2 Identified in DEL Screen
- 16:35** **Erkang Fan**, University of Washington, Seattle, USA
Targeting Nethionyl tRNA Synthetase for Antiparasitic Drug Discovery
- 16:50** TBA
TBA

DAY-3 PROGRAM

Wednesday, DECEMBER 5, 2018

Symposium-IV (Talk: 20 Min | Q&A: 5 Min)

Symposium: Drug Target Discovery in Rare Diseases

Chairs: *Wendy Cornell*, IBM - Healthcare and Life Sciences Research, USA
Paul C. Trippier, Texas Tech University Health Sciences Center, TX, USA

- 09:00** *Paul C. Trippier*, Texas Tech University Health Sciences Center, TX, USA
Multi-modal Small Molecule Therapeutic Development for Batten Disease
- 09:25** *Juergen Lademann*, Professor of Dermatology, Head - CCP, Berlin, Germany
Drug Delivery with Nanoparticles – Science Fiction or Reality
- 09:50** *Jennifer E. Golden*, University of Wisconsin-Madison, WI, USA
Design and Development of First-In-Class Encephalitic Alphavirus Inhibitors with Prophylactic and Therapeutic In Vivo Efficacy
- 10:15** *Paul S. Brookes*, University of Rochester School of Medicine and Dentistry, NY, USA
Role of Mitochondrial Complex II in Cardiac Ischemia, and Optimizing its Inhibition for Therapeutic Benefit
- 10:40** **Coffee Break**
- 11:00** *Hamid Mirzaei*, UT Southwestern Medical Center, TX, USA
Hydralazine: A FDA Approved Drug with Multiple Therapeutic Targets
- 11:25** *Sunil Premawansa*, University of Colombo, Sri Lanka
Involvement of Angiotensin 1 and 2 in Dengue Patients Specifically with Respect to Critical Stage of Dengue Haemorrhagic Fever

Short Talk (Talk: 12 Min | Q&A: 3 Min)

- 11:50** *Minhang Xin*, Xi'an Jiaotong University, P.R. China
Novel 6-aryl Substituted Quinazoline Derivatives as Potent and Selective Phosphoinositide 3-Kinase delta (PI3K δ) Inhibitors
- 12:05** *Adnan Mannan*, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Australia
Investigation of the Molecular Signalling Pathways Delivering Glucose-Lowering Effect of Teucrium Polium

DAY-3 PROGRAM

TUESDAY, DECEMBER 4, 2018

-
- 12:20** **Shadab Mohammad**, *Dean, Faculty of Dental Sciences, King George's Medical University, India*
Therapeutic Interventions in Oral Submucous Fibrosis: An Experimental and Clinical Study
- 12:35** **Johannes Reynisson**, *School of Chemical Sciences, University of Auckland, New Zealand*
Virtual Screening for Novel Atg5-Atg16 Complex Inhibitors for Autophagy Modulation
- 12:50** **Mo Mandegar**, *Tenaya Therapeutics, South San Francisco, CA, USA*
High-Throughput Drug Discovery Using Artificial Intelligence

13:05 Lunch & Departures

NOTE: *This is a Tentative program and subjected to change

*We wish to see you
at
Drug Discovery-2019*



UNITED | Scientific
Group

A non-profit organization (501 C 3 status pending)

8105, Rasor Blvd - Suite #112, PLANO, TX 75024, USA

Ph: +1-408-426-4832, +1-408-426-4833

Toll Free: +1-844-395-4102; Fax: +1-408-426-4869

Email: drugdiscovery@uniscigroup.org

Web: www.unitedscientificgroup.com/conferences/drug-discovery/